Sudhir Krishnankutty
Cardiovascular Core Analysis Laboratory, Stanford University Medical Center, Stanford, CA 94305-5637, USA.
Vasc Health Risk Manag. 2006;2(2):153-6. doi: 10.2147/vhrm.2006.2.2.153.
Circulating lipoprotein-associated phospholipase A2 (Lp-PLA2) is a marker of inflammation that plays a critical role in atherogenesis; its inhibition may have antiatherogenic effects. Studies from the West of Scotland Coronary Prevention Study (WOSCOPS), Monitoring Trends and Determinants in Cardiovascular Diseases (MONICA) and Rotterdam cohorts have shown that Lp-PLA2 is an independent predictor of coronary heart disease (CHD), and the association is not attenuated upon multivariate analysis with traditional risk factors and other inflammatory markers. Studies in subjects with coronary artery disease (CAD) have also shown associations between Lp-PLA2 and cardiovascular risk. At least two recent studies have shown that Lp-PLA2 is a risk predictor for stroke. Overall, epidemiological studies suggest that measurement of Lp-PLA2 in plasma may be a useful in identifying individuals at high risk for cardiovascular events.
循环脂蛋白相关磷脂酶A2（Lp-PLA2）是一种炎症标志物，在动脉粥样硬化形成中起关键作用；抑制它可能具有抗动脉粥样硬化作用。来自苏格兰西部冠心病预防研究（WOSCOPS）、心血管疾病监测趋势和决定因素研究（MONICA）以及鹿特丹队列的研究表明，Lp-PLA2是冠心病（CHD）的独立预测因子，并且在与传统危险因素和其他炎症标志物进行多变量分析时，这种关联并未减弱。对冠状动脉疾病（CAD）患者的研究也表明Lp-PLA2与心血管风险之间存在关联。至少有两项近期研究表明，Lp-PLA2是中风的风险预测因子。总体而言，流行病学研究表明，检测血浆中的Lp-PLA2可能有助于识别心血管事件高危个体。
